Scientists at Lausanne University Hospital (CHUV) and EPFL have discovered a highly potent monoclonal antibody that targets the SARS-CoV-2 spike protein and is effective at neutralizing all variants of concern identified to date, including the delta variant.
Their findings are published in the prestigious journal Cell Reports.
The newly identified antibody was isolated using lymphocytes from COVID-19 patients enrolled in the ImmunoCoV study being carried out by CHUV’s Service of Immunology and Allergy. This antibody is one of the most powerful identified so far against SARS-CoV-2. Structural characterization of the antibody indicates that it binds to an area that is not subjected to mutations of the spike protein. Through this tight interaction, the antibody blocks the spike protein from binding to cells expressing the ACE2 receptor, which is the receptor the virus uses to enter and infect lung cells. That means the antibody halts the viral replication process, enabling a patient’s immune system to eliminate SARS-CoV-2 from the body. This protective mechanism was proven through in vivo tests on hamsters; specimens that were administered the antibody were protected against infection even after receiving a highly infectious dose.
In addition to its antiviral properties, the new antibody is designed to have a lasting effect in humans. A typical unaltered antibody provides protection for up to 3–4 weeks. But this new one can protect patients for 4–6 months. That makes it an interesting preventive-treatment option for unvaccinated at-risk individuals or for vaccinated individuals who are unable to produce an immune response. Immunocompromised patients, organ transplant recipients and those suffering from certain kinds of cancer could be protected against SARS-CoV-2 by receiving antibody injections two or three times a year.
CHUV and EPFL now plan to build on these promising results in association with a start-up company which will perform clinical development and production of the antibody-containing drug, through cooperation and intellectual property agreements. Clinical trials of the drug should begin in late 2022.
Treatment or prophylaxy
This research was conducted jointly by CHUV’s Service of Immunology and Allergy, headed by Prof. Giuseppe Pantaleo and Dr. Craig Fenwick, and by EPFL’s Laboratory of Virology and Genetics, headed by Prof. Didier Trono and Dr. Priscilla Turelli. The research team was able to respond to the pandemic and discover this neutralizing antibody so quickly thanks to the multi-year support of the Swiss Vaccine Research Institute. Prof. Pantaleo’s department at CHUV also received support from the Corona Accelerated R&D in Europe (CARE) program, which is part of the Innovative Medicine Initiative (IMI) – a public-private partnership that seeks to address bottlenecks in the drug discovery and development process in Europe.
The discovery of this new antibody marks a major step forward in the fight against COVID-19. It opens the door to improved treatments for severe forms of the disease and to enhanced prophylactic measures, especially for patients with weakened immune systems. However, this antibody is not intended to replace COVID-19 vaccines, which remain the most effective way to prevent infection.
Original Article: Scientists discover a highly potent antibody against SARS-CoV-2
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Malaria in urban and rural areas of southern Ghana: a survey of parasitaemia, antibodies, and antimalarial practices
A comparative cross-sectional survey was undertaken in two populations, urban and rural, in southern Ghana to assess the impact of urbanization on the prevalence of malaria parasitaemia and antibodies ...
- Using dried blood spots to monitor SARS-CoV-2 antibodies at home
Simultaneously, diagnostic assays were rapidly developed fast and given emergency use authorization (EUA) by the United States Food and Drug Administration (FDA) to identify people with active ...
- Fauci: Profile Of "Omicron" Mutations Suggest It Will Be More Transmissible, Could Evade Existing Antibodies
Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases, is back with the season's hottest new Covid-19 variant, Omicron. He told NBC's "Meet the Press" and ABC's ...
- Denver monoclonal antibody treatment clinic canceled Saturday
A monoclonal antibody treatment clinic by the Colorado Department of Public Health & Environment (CDPHE) was supposed to be available in Denver on Friday and Saturday, but the clinic was unable to ...
- Virus Mimicking Antibodies May Explain Long Haul COVID-19, Rare Vaccine Side Effects
With around 256 million cases and more than 5 million deaths worldwide, the COVID-19 pandemic has challenged scientists and those in the medical field. Researchers are working to find effective ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
SARS-CoV-2 monoclonal antibody
- New variant of SARS-CoV-2 confirmed in South Africa
The National Institute of Communicable Diseases of South Africa (NICD) confirmed on Nov 25, the existence of a new SARS-CoV-2 variant in South Africa, which causes COVID-19, called B.1.1.529.
- Understanding Monoclonal Antibodies and How They Treat COVID-19
While experts agree that getting the vaccine is the best way to prevent COVID-19, we are still researching treatment options if you do, in fact, get sick. This is especially important for those who ...
- COVID patients in the Tampa Bay region can get monoclonal antibody treatments at home
Tampa-based DeliveRxd Pharmacy is offering at-home treatment to eligible residents in 10 counties around the region at no cost to the patient.
- Monoclonal antibodies excel in treating COVID-19 breakthrough cases, Mayo Clinic says
Monoclonal antibody treatment lowers the odds of hospitalization by 77% in patients with COVID-19 breakthrough infections, investigators say. These SARS-CoV-2 reinfections have become more common in ...
- New design may boost potency of monoclonal antibodies against COVID
Monoclonal antibody drugs are among the few treatments available for COVID, providing a lifeline for those at high risk of severe illness and hospitalization. However, the usefulness of these drugs is ...